Medical Minute Series: Experts Perspectives on New Advances in HER2-Mutated NSCLC

Through this series of Medical Minutes with accompanying slides, take home knowledge of current molecular testing and treatment recommendations for patients with HER2-mutated NSCLC and increase your awareness of the latest research on emerging therapies including wild-type EGFR-sparing HER2 tyrosine kinase inhibitors to address ongoing therapeutic needs in this patient population.

Share

Program Content

Activities

NSCLC HER2 Alterations Testing
Medical Minute 1: HER2 Alterations and Testing in NSCLC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2024

Expires: April 16, 2025

NSCLC HER2 Alterations Therapies
Medical Minute 2: Current and Emerging Therapies for Advanced NSCLC With HER2 Mutations and HER2 Overexpression
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 18, 2024

Expires: April 17, 2025

Activities

NSCLC HER2 Alterations Testing
Medical Minute 1: HER2 Alterations and Testing in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2024

Expires: October 15, 2025

NSCLC HER2 Alterations Therapies
Medical Minute 2: Current and Emerging Therapies for Advanced NSCLC With HER2 Mutations and HER2 Overexpression
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2024

Expires: October 16, 2025

Activities

Emerging HER2 Selective  TKIs
Emerging HER2-Selective TKIs for HER2-Mutated NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2024

Expires: November 11, 2025

Faculty

cover img faculity

Misako Nagasaka, MD, PhD

Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California Irvine School of Medicine
Orange, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.